Johnson & Johnson raises outlook after Q2 sales growth

(Sharecast News) - Johnson & Johnson raised its full-year outlook on Wednesday after second-quarter sales rose 6.6% to $25.31bn, ahead of market expectations, while adjusted earnings increased 4.7% to $2.90 per share. Innovative Medicine sales grew 7.8% to $16.38bn, driven by strong demand for Tremfya, Darzalex, Carvykti and Caplyta, offsetting declines in older products including Stelara, while MedTech sales rose 4.5% to $8.93bn.

The healthcare group now expects 2026 reported sales of $100.8bn to $101.4bn and adjusted earnings of $11.60 to $11.75 per share, raising the midpoints to $101.1bn and $11.68 respectively.

Chief executive Joaquin Duato said Johnson & Johnson was on track to exceed $100bn of annual revenue for the first time in its 140-year history.

At 1114 EDT (1614 BST), shares in Johonson & Johnson were down 0.6% in New York at $252.32.

Reporting by Josh White for Sharecast.com.